News Articles

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer INGELHEIM, Germany -Friday 14 December 2018

(BUSINESS WIRE)-- Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or...

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for... -Monday 5 November 2018  

(BUSINESS WIRE)-- Initial effectiveness results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study showed empagliflozin was associated with a 44 percent relative risk reduction in hospitalisation for heart failure (HHF) compared with dipeptidyl peptidase-4...

Boehringer Ingelheim and Lilly present full results of Trajenta®’s... -Thursday 4 October 2018  

(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at...

Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to... -Thursday 4 October 2018  

All investigated doses met the primary efficacy endpoint defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes Full results presented at the 54th European...

Large European real-world study reports effects of Spiolto® Respimat® for people... -Monday 17 September 2018

(BUSINESS WIRE)-- Boehringer Ingelheim announced results from the OTIVACTO study, an observational European real-world study of 7,443 Chronic Obstructive Pulmonary Disease (COPD) patients treated with Spiolto® (tiotropium/olodaterol) Respimat®, which were presented today at the European...

Clinical trial data for nintedanib in patients with advanced IPF published -Sunday 16 September 2018  

INSTAGE® trial results published in the New England Journal of Medicine1 Trial provides clinical data on patients with IPF and severe impairment in gas exchange usually excluded from clinical trials1 Efficacy and safety profile of nintedanib in patients with advanced IPF was...

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years... -Saturday 15 September 2018

INPULSIS®-ON study indicates safety and efficacy of Ofev® (nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS® trials1 Results from INPULSIS®-ON, the open-label extension from the two INPULSIS® Phase III trials, published in Lancet...

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology... -Thursday 13 September 2018

Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics ViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim’s Discovery Research organization, maintaining its innovative biotech heritage and...

Boehringer Ingelheim: New sub-analyses to be presented at ESC Congress 2018 further support positive safety profile of... -Monday 20 August 2018

Nine sub-analyses from RE-DUAL PCI™ and GLORIA™-AF accepted for presentation at ESC Congress 2018 Data from both studies have led to positive update of the SmPC for Pradaxa® in the EU   (BUSINESS WIRE)-- Boehringer Ingelheim today announced that it will present nine...

World Scleroderma Day 2018: Families open up about supporting a loved one with scleroderma, in new video series -Friday 29 June 2018

Boehringer Ingelheim provides platform to families and loved ones of people living with scleroderma with new, insightful stories, sharing ways to cope with and best support a loved one living with this little known disease “I think the disease has brought us closer to each other… I...

New patient survey reveals: For people with atrial fibrillation, reversal of their blood thinning treatment is highly... -Wednesday 27 June 2018

89% of surveyed patients with atrial fibrillation (AF) are aware of potential complications which may arise due to their blood thinning treatment in the event of an emergency The majority (83%) considered it important to know about a medication which could stop the blood thinning...

Systemic Sclerosis World Congress: Inspirational Patient Stories Reveal the Challenging Realities of Living with... -Friday 16 February 2018  

'More Than Scleroderma: The Inside Story' provides real-life stories and education about the life-threatening disease New and truly inspiring patient stories are revealed Help raise awareness of this little-known disease by visiting www.morethanscleroderma.com “I’ve learned how to...

Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To... -Monday 20 November 2017

opnME.com provides scientists with many best-in-class tool molecules supported by comprehensive data packages on one centralized platform for researchers to use The platform offers direct access to molecules for independent research as well as other molecules for partnering with Boehringer...

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery... -Tuesday 14 November 2017  

Empagliflozin (marketed as Jardiance®) reduced the risk of cardiovascular death by 43 percent versus placebo in patients with type 2 diabetes and peripheral artery disease1 In a population at high risk for amputations, no increased risk in lower-limb amputation was observed with...

Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of... -Monday 13 November 2017

(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation for Cyltezo® a biosimilar to Humira® for the treatment of multiple chronic inflammatory diseases in adults and children.* “Cyltezo® is the first biosimilar from...

Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including... -Thursday 2 November 2017

Dicerna to receive up to $201 million in upfront and success-based development and commercialization milestones, excluding royalties, for an undisclosed target The collaboration will investigate a new therapeutic approach that enables addressing previously inaccessible drug targets to...

IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’ -Monday 18 September 2017      

(BUSINESS WIRE)-- IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.1 Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost. However, diagnosis can be...

CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in... -Monday 18 September 2017  

The CHMP of the EMA has issued a positive opinion for an update of the Summary of Product Characteristics (SmPC) for Pradaxa® (dabigatran etexilate) The CHMP recommends to include data showing that catheter ablation can be conducted in patients on 150 mg twice daily Pradaxa®,...

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO® -Friday 15 September 2017

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cyltezo® (adalimumab biosimilar) for the treatment of multiple chronic inflammatory diseases Recommendation based on extensive analytical, pharmacological, non...

Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple... -Sunday 27 August 2017  

(BUSINESS WIRE)-- The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) patients following percutaneous coronary intervention (PCI) and stent placement: results showed significantly lower...

Results 21-40 of 71